Matrixx grabbed by Gryphon
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Private-equity firm Gryphon Investors has acquired Matrixx Initiatives – which markets the Zicam homoeopathic cold treatment brand – from HIG Capital for an undisclosed sum.